{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:26Z","timestamp":1793744186379,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1245\/s10434-014-3651-4","type":"journal-article","created":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T17:21:29Z","timestamp":1397064089000},"page":"2259-2266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Oncolytic Vaccinia Virus as an Adjuvant Treatment to Cytoreductive Surgery for Malignant Peritoneal Mesothelioma"],"prefix":"10.1245","volume":"21","author":[{"given":"Sergio A.","family":"Acuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Ottolino-Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besmira","family":"\u00c7ako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando A.","family":"Angarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Andrea","family":"McCart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,10]]},"reference":[{"issue":"1 Suppl","key":"3651_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X","volume":"75","author":"TM Mack","year":"1995","unstructured":"Mack TM. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer. 1995;75(1 Suppl):211\u201344.","journal-title":"Cancer."},{"issue":"9483","key":"3651_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397\u2013408.","journal-title":"Lancet."},{"issue":"2","key":"3651_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/annonc\/mdp307","volume":"21","author":"P Manzini Vde","year":"2010","unstructured":"Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21(2):348\u201353.","journal-title":"Ann Oncol."},{"issue":"36","key":"3651_CR4","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342.","journal-title":"J Clin Oncol."},{"issue":"6","key":"3651_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","volume":"38","author":"P Mirarabshahii","year":"2012","unstructured":"Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma: an update on treatment. Cancer Treat Rev. 2012;38(6):605\u201312.","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"3651_CR6","first-page":"207","volume":"18","author":"PH Sugarbaker","year":"2004","unstructured":"Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2: perioperative intraperitoneal chemotherapy. Oncology (Williston Park). 2004;18(2):207\u201319; discussion 220-2, 227-8, 230.","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"3651_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ejso.2006.03.012","volume":"32","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):686\u201391.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"3651_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.amjsurg.2010.04.010","volume":"201","author":"PH Sugarbaker","year":"2011","unstructured":"Sugarbaker PH. Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? Am J Surg. 2011;201(2):157\u20139.","journal-title":"Am J Surg."},{"issue":"5","key":"3651_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jgm.877","volume":"8","author":"PS Adusumilli","year":"2006","unstructured":"Adusumilli PS, Stiles BM, Chan MK, et al. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med. 2006;8(5):603\u201315.","journal-title":"J Gene Med."},{"issue":"7","key":"3651_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/01243894-200609000-00017","volume":"1","author":"ZB Zhu","year":"2006","unstructured":"Zhu ZB, Makhija SK, Lu B, et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol. 2006;1(7):701\u201311.","journal-title":"J Thorac Oncol."},{"issue":"8","key":"3651_CR11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jgm.1486","volume":"12","author":"S Kubo","year":"2010","unstructured":"Kubo S, Kawasaki Y, Yamaoka N, et al. Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med. 2010;12(8):681\u201392.","journal-title":"J Gene Med."},{"issue":"19","key":"3651_CR12","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","volume":"69","author":"CL Willmon","year":"2009","unstructured":"Willmon CL, Saloura V, Fridlender ZG, et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 2009;69(19):7713\u201320.","journal-title":"Cancer Res."},{"issue":"1","key":"3651_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/hum.2009.088","volume":"21","author":"V Saloura","year":"2010","unstructured":"Saloura V, Wang LC, Fridlender ZG, et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther. 2010;21(1):51\u201364.","journal-title":"Hum Gene Ther."},{"issue":"10","key":"3651_CR14","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/1535-7163.MCT-10-0090","volume":"9","author":"GR Silberhumer","year":"2010","unstructured":"Silberhumer GR, Brader P, Wong J, et al. Genetically engineered oncolytic newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther. 2010;9(10):2761\u20139.","journal-title":"Mol Cancer Ther."},{"issue":"12","key":"3651_CR15","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","volume":"68","author":"A Gauvrit","year":"2008","unstructured":"Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008;68(12):4882\u201392.","journal-title":"Cancer Res."},{"issue":"8","key":"3651_CR16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/hum.2008.036","volume":"19","author":"KJ Kelly","year":"2008","unstructured":"Kelly KJ, Woo Y, Brader P, et al. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther. 2008;19(8):774\u201382.","journal-title":"Hum Gene Ther."},{"issue":"20","key":"3651_CR17","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","volume":"67","author":"Q Zhang","year":"2007","unstructured":"Zhang Q, Yu YA, Wang E, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007;67(20):10038\u201346.","journal-title":"Cancer Res."},{"issue":"7362","key":"3651_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","volume":"477","author":"CJ Breitbach","year":"2011","unstructured":"Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99\u2013102.","journal-title":"Nature."},{"issue":"6","key":"3651_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","volume":"9","author":"BH Park","year":"2008","unstructured":"Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533\u201342.","journal-title":"Lancet Oncol."},{"issue":"10","key":"3651_CR20","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/mt.2011.132","volume":"19","author":"TH Hwang","year":"2011","unstructured":"Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19(10):1913\u201322.","journal-title":"Mol Ther."},{"issue":"24","key":"3651_CR21","first-page":"8751","volume":"61","author":"JA McCart","year":"2001","unstructured":"McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61(24):8751\u20137.","journal-title":"Cancer Res."},{"issue":"6","key":"3651_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.2910520609","volume":"52","author":"MR Davis","year":"1992","unstructured":"Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992;52(6):881\u22126.","journal-title":"Int J Cancer."},{"issue":"3","key":"3651_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ymthe.2004.06.158","volume":"10","author":"JA McCart","year":"2004","unstructured":"McCart JA, Mehta N, Scollard D, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther. 2004;10(3):553\u201361.","journal-title":"Mol Ther."},{"issue":"6","key":"3651_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s004230050246","volume":"384","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon\u2019s role. Langenbecks Arch Surg. 1999;384(6):576\u201387.","journal-title":"Langenbecks Arch Surg."},{"issue":"6","key":"3651_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00268-005-7583-9","volume":"29","author":"M Jansen","year":"2005","unstructured":"Jansen M, Treutner KH, Jansen PL, et al. Inhibition of gastric cancer cell adhesion in nude mice by inraperitoneal phospholipids. World J Surg. 2005;29(6):708\u201314.","journal-title":"World J Surg."},{"issue":"3","key":"3651_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.cgt.7700558","volume":"10","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther. 2003;10(3):215\u201323.","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"3651_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1067\/mtc.2002.122297","volume":"124","author":"MI Ebright","year":"2002","unstructured":"Ebright MI, Zager JS, Malhotra S, et al. Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg. 2002;124(1):123\u20139.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"12","key":"3651_CR28","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1517\/14656560903044974","volume":"10","author":"PH Sugarbaker","year":"2009","unstructured":"Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: The Washington Cancer Institute approach. Expert Opin Pharmacother. 2009;10(12):1965\u201377.","journal-title":"Expert Opin Pharmacother."},{"issue":"3","key":"3651_CR29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ijc.28048","volume":"133","author":"P Bertino","year":"2013","unstructured":"Bertino P, Panigada M, Soprana E, et al. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer. 2013;133(3):612\u201323.","journal-title":"Int J Cancer."},{"issue":"9","key":"3651_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/ijc.25557","volume":"128","author":"M Ho","year":"2011","unstructured":"Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer. 2011;128(9):2020\u201330.","journal-title":"Int J Cancer."},{"issue":"5","key":"3651_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","volume":"8","author":"Y Feng","year":"2009","unstructured":"Feng Y, Xiao X, Zhu Z, et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther. 2009;8(5):1113\u20138.","journal-title":"Mol Cancer Ther."},{"issue":"8","key":"3651_CR32","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/mt.2010.98","volume":"18","author":"BW Bridle","year":"2010","unstructured":"Bridle BW, Stephenson KB, Boudreau JE, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther. 2010;18(8):1430\u20139.","journal-title":"Mol Ther."},{"issue":"2","key":"3651_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2009.283","volume":"18","author":"K Ottolino-Perry","year":"2010","unstructured":"Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010;18(2):251\u201363.","journal-title":"Mol Ther."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-014-3651-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3651-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:41:32Z","timestamp":1746178892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-014-3651-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["3651"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3651-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,10]]},"assertion":[{"value":"6 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2014","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}